Association of FTH1-expressing circulating tumor cells with efficacy of neoadjuvant chemotherapy for patients with breast cancer: a prospective cohort study

Jia, Shijie, Yang, Yaping, Zhu, Yingying, Yang, Wenqian, Ling, Li, Wei, Yanghui, Fang, Xiaolin, Lin, Qun, Hamaï, Ahmed, Mehrpour, Maryam, Gao, Jingbo, Tan, Weige, Xia, Yuan, Chen, Jiayi, Jiang, Wenguo ORCID: https://orcid.org/0000-0002-3283-1111 and Gong, Chang 2023. Association of FTH1-expressing circulating tumor cells with efficacy of neoadjuvant chemotherapy for patients with breast cancer: a prospective cohort study. The Oncologist 10.1093/oncolo/oyad195

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

Background The association between different phenotypes and genotypes of circulating tumor cells (CTCs) and efficacy of neoadjuvant chemotherapy (NAC) remains uncertain. This study was conducted to evaluate the relationship of FTH1 gene-associated CTCs (F-CTC) with/without epithelial-mesenchymal transition (EMT) markers, or their dynamic changes with the efficacy of NAC in patients with non-metastatic breast cancer. Patients and Methods This study enrolled 120 patients with non-metastatic breast cancer who planned to undergo NAC. The FTH1 gene and EMT markers in CTCs were detected before NAC (T0), after 2 cycles of chemotherapy (T1), and before surgery (T2). The associations of these different types of CTCs with rates of pathological complete response (pCR) and breast-conserving surgery (BCS) were evaluated using the binary logistic regression analysis. Results F-CTC in peripheral blood ≥1 at T0 was an independent factor for pCR rate in patients with HER2-positive (odds ratio [OR]=0.08, 95% confidence interval [CI], 0.01-0.98, P = .048). The reduction in the number of F-CTC at T2 was an independent factor for BCS rate (OR = 4.54, 95% CI, 1.14-18.08, P = .03). Conclusions The number of F-CTC prior to NAC was related to poor response to NAC. Monitoring of F-CTC may help clinicians formulate personalized NAC regimens and implement BCS for patients with non-metastatic breast cancer.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Oxford University Press
ISSN:	1083-7159
Date of First Compliant Deposit:	2 July 2023
Date of Acceptance:	23 May 2023
Last Modified:	15 Nov 2024 01:15
URI:	https://orca.cardiff.ac.uk/id/eprint/160762

Actions (repository staff only)

Edit Item